GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Natural Capsules Ltd

Natural Capsules Q2 FY27 Revenues ₹51.15 cr, Net Loss ₹(4.22) cr

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 15 Nov 2026, 09:23 PM IST  ·  BSE ID: d60e082a-ae00-433d-84c8-3af739b7eb23
View Original BSE Filing (PDF)
💡
In Simple Terms
Natural Capsules announced its latest financial results, showing ₹51.15 cr in Q2 FY27 revenue and a net loss.
🤖 AI Summary
  • Natural Capsules reported Q2 FY27 revenues of ₹51.15 cr and a net loss of ₹(4.22) cr.
  • Half-year FY27 revenues stood at ₹99.86 cr, with a net loss of ₹(9.97) cr.
  • The company converted HPMC lines to gelatin to increase volumes, with a second line conversion underway for H2 FY27.
  • New customer additions include Mankind Pharma, and an audit by Zydus Lifesciences was successfully completed.
  • API operations focus on closing loss-making lines, regulatory filings (WHO GMP, COPP), and a pipeline of 16 molecules for US DMF/CEP.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Q2 FY27 Revenues
₹ 51.15 cr
40%
Q2 FY27 EBITDA
₹ 3.01 cr
Q2 FY27 EBITDA Margins
5.88%
781 BPS
Q2 FY27 PAT
₹ (4.22) cr
H1 FY27 Revenues
₹ 99.86 cr
24%
H1 FY27 EBITDA
₹ 4.13 cr
H1 FY27 EBITDA Margins
4.14%
538 BPS
H1 FY27 PAT
₹ (9.97) cr
🏢 How This Affects the Company
📈
Business Impact
The strategic conversion of HPMC lines to gelatin aims to better utilize capacity and drive volume growth, diversifying product offerings. Customer additions like Mankind Pharma and successful Zydus audit indicate market penetration and future business expansion in the capsules segment.
💰
Financial Impact
The company reported a net loss of ₹(4.22) cr for Q2 FY27 and ₹(9.97) cr for H1 FY27. While realisations improved, managing rising gelatine, coal, and oil prices remains a factor in maintaining EBITDA margins.
⚙️
Operational Impact
Capacity conversion from HPMC to gelatin lines reflects a shift in manufacturing focus to meet market demand. The appointment of a new CEO for API operations signals a restructuring and renewed strategic direction for that business segment.
⚠️
Risk Impact
Challenges in container availability and freight rates persist, potentially impacting logistics costs. Anticipated increases in gelatine, coal, and oil prices represent a cost risk, though management expects to pass these on to customers.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, specifically the reported net loss of ₹(4.22) cr for Q2 FY27 and ₹(9.97) cr for H1 FY27. The strategic operational changes could impact future returns.
🔍
Management Signal
Management is strategically converting idle HPMC lines to gelatin to optimize capacity utilization and drive volume growth. The focus on API business restructuring and regulatory filings indicates a long-term growth strategy.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor impact of second HPMC line conversion on volumes.
Progress on WHO GMP certification and COPP filings for API products.
Updates on new contracts for contract manufacturing to absorb synthesis block capacity.
MEDIUM RISK Net losses continue, and rising raw material costs and logistics challenges could pressure margins if not fully passed on.
💡 Investor Takeaway
Natural Capsules reported Q2 FY27 revenues of ₹51.15 cr, marking a 40% Y-o-Y increase, alongside a net loss of ₹(4.22) cr. Half-year FY27 revenues were ₹99.86 cr with a net loss of ₹(9.97) cr. The company converted HPMC lines to gelatin, adding new customers and progressing API regulatory filings.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 revenues increased by 26% Q-o-Q and 40% Y-o-Y, reaching ₹51.15 cr, driven by higher volumes from capacity conversion.
  • Added new customers like Mankind Pharma and completed Zydus Lifesciences audit, indicating robust demand and potential for future business growth.

⚠️ Concerns

  • Reported a net loss of ₹(4.22) cr in Q2 FY27 and ₹(9.97) cr for H1 FY27, despite revenue growth and stable realisations.
  • Logistics challenges with container availability and freight rates persist, alongside expectations of rising raw material costs (gelatine, coal, oil).
📅 Company Track Record
Natural Capsules reported Q4 FY26 revenue of Rs 58.45 Cr and FY26 PAT of Rs (24.66) Cr. The company's new HPMC line was ready in Q4 FY26. Prior filings noted a ₹10,01,25,000/- preferential equity allotment to its promoter in Q2 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Natural Capsules' Q2 FY27 revenues?
Natural Capsules reported revenues of ₹51.15 cr for the quarter ended September 30, 2026 (Q2 FY27).
What was Natural Capsules' net profit or loss in Q2 FY27?
Natural Capsules reported a net loss (PAT) of ₹(4.22) cr for Q2 FY27.
What were Natural Capsules' half-year FY27 revenues and net profit?
For the half-year ended September 30, 2026 (H1 FY27), Natural Capsules reported revenues of ₹99.86 cr and a net loss (PAT) of ₹(9.97) cr.
What strategic operational changes did Natural Capsules make in Q2 FY27?
Natural Capsules strategically converted HPMC lines to gelatin lines to utilize idle capacity and drive additional gelatin volumes during Q2 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel